Navigation Links
Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:11/9/2012

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --Event:

HCV Connection Media BriefingDate:

Monday, November 12Time:

7:45 a.m. Eastern Standard TimeWhere:

Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199; Also available by Webcast (link will be provided upon request)The content of the media briefing will include the following themes and information:

  • An overview of HCV and the current epidemic worldwide
  • A compelling historical and scientific context for understanding the new era of HCV therapies and the emergence of patient-guided therapy
  • A brief review of first and second-generation direct-acting antiviral therapies, including important new developments in drug discovery
  • A detailed look at Achillion Pharmaceutical's portfolio aimed at curing HCV in a complex and diverse patient population
  • Following the briefing there will be a Question & Answer session with leading experts in HCV including:

  • Fred Poordad, MD, Chief Medical Officer of the Texas Liver Institute and Alamo Medical Research, San Antonio, Texas
  • Andrew Muir, MD, Director, Gastroenterology and Hepatology Research Group, Duke Clinical Research Institute, Durham, North Carolina
  • The session will also be moderated by Lisa Stark of ABC News
  • Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified and advanced multiple therapeutic compounds, many with novel mechanisms or attributes. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C (HCV) and resistant bacterial infections. Please visit www.achillion.com for additional information.


    '/>"/>
    SOURCE Achillion Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
    2. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
    4. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
    5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    6. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
    7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
    8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    9. MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
    11. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... YORK , December 2, 2016 ... the trading session in red, while the Dow Jones Industrial ... at the close of US markets, which prompted Stock-callers this ... stocks: NuVasive Inc. (NASDAQ: NUVA ), Smith & ... (NASDAQ: NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
    (Date:12/2/2016)... LONDON , Dec. 1, 2016 Around ... every country, region and each habitable land present over ... haunt every individual once in a life time this ... proper care available until now. Given the steady increase ... mortality, together with the spiraling healthcare costs of treatment, ...
    (Date:11/30/2016)... Research and Markets has announced the addition ... - MedCore" report to their offering. ... , , The cerebrospinal fluid ... healthy individuals, it is circulated though the brain and its ventricles, the ... of CSF surrounding the brain changes significantly. As ...
    Breaking Medicine Technology:
    (Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture ... brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that there had ... handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from ...
    (Date:11/30/2016)... FL (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new eating ... partial hospitalization and intensive outpatient treatment for adults and adolescents, both males and ...
    (Date:11/30/2016)... , ... November 30, 2016 , ... ... injured workers have been a focus of public policymakers and system stakeholders in ... Institute (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth Edition ...
    (Date:11/30/2016)... ... November 30, 2016 , ... ... clinical research community that the FDA Binding Guidance goes into effect next month. ... formats listed in the FDA Data Standards Catalog. The current FDA Data Standards ...
    (Date:11/30/2016)... ... 2016 , ... U.S. Security Associates (USA) announced the acquisition ... Richmond, Virginia. The acquisition further strengthens USA’s capabilities within the expanding healthcare ... prides itself on 100% client-retention to the healthcare industry. In addition, ODS has ...
    Breaking Medicine News(10 mins):